Home / Content / B2B Connect / Pharma / Glenmark receives US FDA approval for hypertension drug nebivolol

Glenmark receives US FDA approval for hypertension drug nebivolol

It is also eligible for 180 days exclusivity for the drug, a generic version of Forest's Bystolic

Premium

Glenmark office

Last Updated : May 29 2017 | 12:50 PM IST

Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration (FDA) for the hypertension drug nebivolol, for tablets of strengthen 2.5 mg, 5 mg, 10 mg and 20 mg. The approved product is the generic version of Bystolic tablet of Forest Laboratories Llc.

With respect to 180-day generic drug exclusivity, the FDA noted that Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for nebivolol tablets. Therefore, with this approval, the company may be eligible for 180 days of generic drug exclusivity for nebivolol tablets.

Nebivolol, which belongs

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in